---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-028027"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:22:31.492456+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sana Q2 net loss $72.5M; cash runway extended into 2025 on manufacturing move savings

## Summary
- Cash position $579.6M at June 30, 2022, down $167.3M from Dec 31, 2021.
- Q2 net loss $72.5M ($0.39 per share) vs net income $18.7M in Q2 2021.
- Expect cash runway into 2025; ~$100M cost savings from relocating manufacturing to Bothell, WA.
- Plan to file INDs in 2022 for SC291 and SG295; SC451 (type 1 diabetes) IND in 2023.
- Presented preclinical data showing survival of HIP pancreatic islet cells, cardiomyocytes, RPE cells in NHP.

## SEC filing metadata
- accession: 0001564590-22-028027
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000156459022028027/0001564590-22-028027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000156459022028027/sana-8k_20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-028027
- JSON: https://secwatch.observer/filing/0001564590-22-028027.json
- Plain text: https://secwatch.observer/filing/0001564590-22-028027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.